Skip to main content
Skip to footer

Please have a representive contact me.

Shop Account Login Cart (0) 888-986-6696

Compliance

FDA Guidance for Industry

RichSource is the distributor of the RICHGEN product line manufactured by a high level tissue processing lab in Florida. The lab manufactured biologics are regulated as human cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act, FDA and ISO 13485 guidelines. FDA registered, cGMP, GMP and GTP compliant.

Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Title 21 – Food and Drugs Part 1271.10 – Human Cells, Tissues, and Cellular and Tissue- Based Products - HCT/P’s

AATB Guidance Documents

Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use

Title 21 – Current Good Tissue Practice Sec. 1271.150

Current Good Manufacturing Practice Regulations cGMP

Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271

Tissue and Tissue Products

Footer

Internal Footer Image

The RICHGEN® product line is distributed by RichSource, a Florida Corporation. Copyright © 2018-2019. | Privacy Policy | Terms & Conditions | Disclaimer

Caution – be careful what you use:

Predictive Biotech single material Wharton jelly independent lab test by Dr. Spencer shows only 2.4% viability. See Predictive screen shot.
Also, the test showed only 2/3 the quantity of cells versus what is promoted. Click here to see the video.

Bone marrow cell extraction has resulted in serious infections and the cell counts reduce dramatically with age. See the chart in our brochure. Adipose cell extraction has resulted in adverse reactions causing blindness and stroke. Both procedures cause patient discomfort.

Is bone marrow surgery risky? NJ Principal dies donating bone marrow. Do bone marrow extraction practices follow processing and labeling FDCA and PHSA regulations? See United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Utah Cord Bank lab test tissue clump debris in photo. Test shows no viability.

Mimedx Injectables Do Not Meet FDA Standards – WSJ article.

Efficacy of PRP Study: No improvement

FDA rules exosomes products being sold are not licensed and approved.

RichSource is rapidly educating practitioners who are ready to replace risky, time consuming and outdated techniques. In addition, the RichSource superior products are umbilical cord blood free. Our standards are very advanced in producing the most reliable injectables in full compliance.

The Truth About Bone Marrow Aspirate

See Regenexx: United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Caution – be careful what you use:

Predictive Biotech Wharton jelly product viability independent testing is only 2.4% versus what is claimed per Dr. Eliott Spencer, PhD.

Bone marrow cell extraction has resulted in serious infections and the cell counts reduce dramatically with age. See the chart in our brochure. Adipose cell extraction has resulted in adverse reactions causing blindness and stroke. Both procedures cause patient discomfort.

Is bone marrow surgery risky? NJ Principal dies donating bone marrow. Do bone marrow extraction practices follow processing and labeling FDCA and PHSA regulations? See United States of America v. Regenerative Sciences, LLC No. 12-5254 Appellate Ruling dated February 4, 2014.

Utah Cord Bank lab test tissue clump debris in photo.

Mimedx Injectables Do Not Meet FDA Standards – WSJ article.

Efficacy of PRP Study: No improvement

Umbilical Cord “Stem Cell” Infusion Side Effects: What you need to know…

About
Physicians
SHOP
Aestheticians
Science
Compliance
News
Contact